CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX)

Historical Holders from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.00001 par value per share
Symbol
CTMX on Nasdaq
Shares outstanding
165,547,872
Price per share
$4.26
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
137,376,737
Total reported value
$438,231,708
% of total 13F portfolios
0%
Share change
+4,071,628
Value change
+$24,416,720
Number of holders
101
Price from insider filings
$4.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +34% $65,458,695 +$16,344,817 20,519,967 +33% FMR LLC 31 Oct 2025
Venrock Healthcare Capital Partners III, L.P. 9.4% +15% $49,641,185 +$8,195,110 15,561,500 +20% Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
Longitude Capital Partners V, LLC 7.3% $8,192,307 11,538,461 Longitude Capital Partners V, LLC 13 May 2025
TANG CAPITAL MANAGEMENT LLC 7% -18% $27,442,842 +$10,782,636 11,065,662 +65% TANG CAPITAL MANAGEMENT, LLC 30 Jun 2025
PERCEPTIVE ADVISORS LLC 5.9% $22,458,029 9,680,185 Perceptive Advisors LLC 14 Aug 2025
VANGUARD GROUP INC 6% $21,292,132 9,379,794 The Vanguard Group 30 Jun 2025
ORBIMED ADVISORS LLC 5.4% $20,984,520 8,461,500 OrbiMed Advisors LLC 30 Jun 2025
BIOTECHNOLOGY VALUE FUND L P 3.5% -47% $17,250,001 -$17,250,001 5,769,231 -50% BVF PARTNERS L P/IL 03 Jul 2025
Point72 Asset Management, L.P. 2.5% -52% $12,978,754 -$12,811,193 4,068,575 -50% Point72 Asset Management, L.P. 30 Sep 2025
Seven Fleet Partners LP 0.2% $267,784 377,161 Seven Fleet Partners LP 13 May 2025
Seven Fleet Capital Management LP 0.02% $155,985 48,898 Seven Fleet Master Fund LP 30 Sep 2025
As of 30 Sep 2025, CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 101 institutional shareholders filing 13F forms. They hold 137,376,737 shares. of 165,547,872 outstanding shares (83%) .

Top 25 institutional shareholders own 75% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
VR ADVISER, LLC 9.4% 15,561,500 +11% 2.8% $49,641,185
FMR LLC 9.3% 15,396,200 +67% 0% $49,113,878
TANG CAPITAL MANAGEMENT LLC 6.7% 11,065,662 0% 1.4% $35,299,462
PERCEPTIVE ADVISORS LLC 5.8% 9,680,185 +38% 0.9% $30,879,790
VANGUARD GROUP INC 5.4% 8,947,807 -4.6% 0% $28,543,505
ORBIMED ADVISORS LLC 5.1% 8,461,500 0% 0.65% $26,992,185
Commodore Capital LP 4.6% 7,692,300 0% 1.2% $24,538,437
BAKER BROS. ADVISORS LP 2.6% 4,250,826 +22% 0.1% $13,560,135
Point72 Asset Management, L.P. 2.5% 4,068,575 -50% 0.03% $12,978,754
ADAR1 Capital Management, LLC 2.4% 4,045,414 +31% 1.3% $12,904,871
Balyasny Asset Management L.P. 2.4% 3,913,081 +37% 0.03% $12,482,728
Kynam Capital Management, LP 2.2% 3,646,503 +69% 0.87% $11,632,345
RTW INVESTMENTS, LP 2.1% 3,461,500 0% 0.14% $11,042,185
Ikarian Capital, LLC 2% 3,372,616 2.4% $10,758,645
Vivo Capital, LLC 1.7% 2,884,615 -50% 0.74% $9,201,922
RA CAPITAL MANAGEMENT, L.P. 1.6% 2,661,331 0% 0.1% $8,489,646
RENAISSANCE TECHNOLOGIES LLC 1.5% 2,545,260 +37% 0.01% $8,119,379
BlackRock, Inc. 1.4% 2,381,912 -0.27% 0% $7,598,299
Woodline Partners LP 1.4% 2,337,005 +0% 0.04% $7,455,046
CITADEL ADVISORS LLC 1.1% 1,800,435 +2006% 0% $5,743,387
GEODE CAPITAL MANAGEMENT, LLC 0.95% 1,569,298 -10% 0% $5,008,010
MILLENNIUM MANAGEMENT LLC 0.84% 1,386,863 +494% 0% $4,424,093
Financial Engines Advisors L.L.C. 0.83% 1,381,357 0.01% $4,406,529
BOOTHBAY FUND MANAGEMENT, LLC 0.75% 1,237,057 0.1% $3,946,212
MARSHALL WACE, LLP 0.67% 1,104,993 -53% 0% $3,524,928

Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 645,805 $2,750,885 -$358,774 $4.26 2
2025 Q3 137,376,737 $438,231,708 +$24,416,720 $3.19 101
2025 Q2 133,305,109 $302,602,132 +$213,797,054 $2.27 82
2025 Q1 45,180,958 $28,723,084 -$1,507,772 $0.64 63
2024 Q4 46,714,805 $48,111,898 -$6,381,441 $1.03 68
2024 Q3 51,193,741 $60,427,306 +$480,690 $1.18 69
2024 Q2 50,687,257 $61,863,474 +$334,609 $1.22 73
2024 Q1 44,548,308 $97,118,414 +$26,024,246 $2.18 85
2023 Q4 32,640,376 $50,592,909 +$410,206 $1.55 66
2023 Q3 32,393,313 $41,785,804 -$2,418,556 $1.29 61
2023 Q2 34,120,916 $58,688,106 -$2,378,087 $1.72 66
2023 Q1 35,594,054 $53,751,153 -$933,381 $1.51 74
2022 Q4 35,979,014 $120,192,376 -$724,794 $1.60 77
2022 Q3 36,281,610 $52,604,898 -$18,986,577 $1.45 76
2022 Q2 45,579,430 $83,410,352 -$17,825,825 $1.83 86
2022 Q1 53,661,262 $143,355,949 -$1,754,233 $2.67 112
2021 Q4 54,342,875 $235,299,521 -$5,313,006 $4.33 106
2021 Q3 53,978,233 $274,775,521 -$17,338,127 $5.09 111
2021 Q2 56,688,576 $358,879,555 +$4,313,452 $6.33 119
2021 Q1 54,613,642 $422,156,729 +$130,257,296 $7.73 123
2020 Q4 37,995,365 $248,881,255 +$5,576,359 $6.55 123
2020 Q3 36,841,081 $245,069,950 -$11,639,890 $6.65 128
2020 Q2 37,758,348 $314,514,192 +$15,532,613 $8.33 133
2020 Q1 36,087,916 $276,879,388 +$244,869 $7.67 113
2019 Q4 36,001,618 $299,160,261 -$9,333,104 $8.31 119
2019 Q3 35,837,109 $264,433,175 -$1,377,891 $7.38 111
2019 Q2 35,647,194 $399,598,509 -$8,094,164 $11.22 108
2019 Q1 36,897,584 $396,629,592 -$12,805,896 $10.75 110
2018 Q4 37,768,617 $569,884,178 -$2,745,916 $15.10 108
2018 Q3 37,780,542 $697,391,587 +$95,602,749 $18.50 119
2018 Q2 32,308,752 $738,633,935 +$66,042,910 $22.86 139
2018 Q1 28,622,740 $814,197,912 +$73,379,749 $28.45 136
2017 Q4 30,146,848 $636,945,631 +$56,049,834 $21.11 119
2017 Q3 24,242,512 $440,733,363 +$42,038,227 $18.17 97
2017 Q2 22,105,676 $342,719,825 +$44,092,931 $15.50 89
2017 Q1 19,204,130 $331,600,145 +$58,337,064 $17.27 86
2016 Q4 16,857,707 $185,279,386 +$14,954,410 $10.99 68
2016 Q3 19,725,140 $242,759,481 +$18,076,577 $15.68 61
2016 Q2 18,845,409 $149,178,103 +$16,034,432 $10.21 59
2016 Q1 12,778,869 $164,816,000 +$3,379,204 $12.90 47
2015 Q4 12,469,279 $258,260,359 +$239,918,359 $20.87 47